Skip to main content

Advertisement

SpringerLink
Log in

Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Nab-paclitaxel plus gemcitabine (Nab-Gem) represents one of the standard regimen for first-line treatment of metastatic pancreatic adenocarcinoma (mPDAC). However, few data are available in mPDAC relapsed after gemcitabine as adjuvant treatment. Our study aims to evaluate the efficacy and feasibility of Nab-Gem as first-line treatment for mPDAC patients previously treated with adjuvant treatment. We retrospectively analyzed the safety and efficacy data of 36 patients, who received first-line Nab-Gem after gemcitabine as adjuvant treatment. All patients received gemcitabine after radical surgery. Median disease-free survival was 12 months (95% CI 9.7–14.3); at relapse, all patients received Nab-Gem. We observed an objective response rate and disease control rate of 11.1% and 63.9%, respectively. With a median follow-up of 47 months, median progression-free survival was 5 months (95% CI 1.0–9.0), whereas median overall survival (OS) was 13 months (95% CI 5.5–20.5). Median OS was higher in patients with a relapse ≥ 7 months after the end of adjuvant treatment than in patients relapsed < 7 months (14 vs. 8 months, respectively, p: 0.52). Our results show that first-line Nab-Gem is feasible and effective in patients previously treated with gemcitabine as adjuvant treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Miller K, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551 Epub 2019 Jan 8.

    Article  PubMed  Google Scholar 

  2. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22:9694–705.

    Article  Google Scholar 

  3. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary managenement of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836–47.

    Article  Google Scholar 

  4. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.

    Article  CAS  Google Scholar 

  5. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–24.

    Article  CAS  Google Scholar 

  6. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines. Ann Oncol. 2015;26(suppl 5):v56–68.

    Article  Google Scholar 

  7. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX versus gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.

    Article  CAS  Google Scholar 

  8. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006–10.

    Article  Google Scholar 

  9. Klinkenbijl J, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg. 1999;230:776–82.

    Article  CAS  Google Scholar 

  10. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.

    Article  CAS  Google Scholar 

  11. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–85.

    Article  CAS  Google Scholar 

  12. Stocken DD, Büchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92(8):1372–81.

    Article  CAS  Google Scholar 

  13. Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34:2541–56.

    Article  Google Scholar 

  14. Gbolahan OB, Tong Y, Sehdev A, O’Neil B, Shahda S. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer. 2019;19(1):468. https://doi.org/10.1186/s12885-019-5630-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  Google Scholar 

  16. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  Google Scholar 

  17. De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, et al. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer. 2016;16(1):709. https://doi.org/10.1186/s12885-016-2671-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.

    Article  CAS  Google Scholar 

  19. CTCAE 4.03. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published: May 28, 2009 (v4.03: June 14, 2010). US Department of Health and Human Services. Nacional Cancer Institute.

  20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  Google Scholar 

  21. Wang-Gillam A, Li CP, Bodoky G, et al. NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545–57.

    Article  CAS  Google Scholar 

  22. Lee B, Lipton L, Cohen J, Tie J, Javed AA, Li L, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localised pancreatic cancer. Ann Oncol. 2019. https://doi.org/10.1093/annonc/mdz200.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(34):4548–54. https://doi.org/10.1200/JCO.2011.36.5742 Epub 2011 Oct 3.

    Article  CAS  Google Scholar 

  24. Kuczynski EA, Sargent DJ, Grothey A, et al. Drug rechallenge and treatment beyond progression—implications for drug resistance. Nat Rev Clin Oncol. 2013;10(10):571–87. https://doi.org/10.1038/nrclinonc.2013.158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank all patients and their families for the participation in this study.

Funding

This research received no external funding

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Precision Medicine, University of Study of Campania “L. Vanvitelli”, via Pansini n.5, 80131, Naples, Italy

    Angelica Petrillo, Annalisa Pappalardo, Luca Pompella, Giuseppe Tirino, Maria Maddalena Laterza, Marianna Caterino, Anna Ventriglia, Michele Orditura, Fortunato Ciardiello & Ferdinando De Vita

  2. Division of Medical Oncology, AORN, “A Cardarelli”, Naples, Italy

    Filomena Calabrese & Maria Biglietto

  3. Department of Cardiothoracic Sciences, University of Study of Campania “L. Vanvitelli”, Via Sergio Pansini 5, 80131, Naples, Italy

    Giovanni Conzo

  4. Department of Oncological Surgery, A.O.R.N. “A. Cardarelli”, Naples, Italy

    Carlo Molino

Authors
  1. Angelica Petrillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annalisa Pappalardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luca Pompella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe Tirino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Filomena Calabrese
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Maddalena Laterza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marianna Caterino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anna Ventriglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michele Orditura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giovanni Conzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Carlo Molino
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Fortunato Ciardiello
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Maria Biglietto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ferdinando De Vita
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, FDV and APe; methodology and formal analysis, APe; investigation, APe, APa, LP, GT, FCa, MML, MC, AV, MO, GC, CM, MB; resources, APa, LP; data curation, APa, FCa; writing—original draft preparation, APe, APa, LP; writing—review and editing, APe, APa, LP, FCi, FDV; supervision, FCi, MB, FDV.

Corresponding authors

Correspondence to Angelica Petrillo or Ferdinando De Vita.

Ethics declarations

Conflict of interest

A.Pe: honoraria from Lilly; M.O: Honoraria from Italfarmaco, EISAI, epionpharma, Roche; F.Ci: Advisory Boards: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, BMS, Celgene, Lilly; Institutional Research Grants: Bayer, Roche, Merck, Amgen, AstraZeneca, Takeda; F.D.V: Advisory Boards: Roche, Amgen, Celgene, Lilly. The authors declare that all these conflicts of interest are not connected with the issue of this paper. The other authors have no conflicts of interest to declare.

Ethical approval

All patients, at the time of therapy, signed informed consent about the use of their data for future medical research. The analysis was carried out with the approval of Ethics Committee of AOU “Luigi Vanvitelli”—AORN Ospedali dei Colli, of our institution.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petrillo, A., Pappalardo, A., Pompella, L. et al. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Med Oncol 36, 83 (2019). https://doi.org/10.1007/s12032-019-1306-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-019-1306-9

Keywords

Search

Navigation